MX2022016272A - Derivados de tetrazol como inhibidores de trpa1. - Google Patents
Derivados de tetrazol como inhibidores de trpa1.Info
- Publication number
- MX2022016272A MX2022016272A MX2022016272A MX2022016272A MX2022016272A MX 2022016272 A MX2022016272 A MX 2022016272A MX 2022016272 A MX2022016272 A MX 2022016272A MX 2022016272 A MX2022016272 A MX 2022016272A MX 2022016272 A MX2022016272 A MX 2022016272A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrazole derivatives
- trpa1
- trpa1 inhibitors
- inhibitors
- derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003536 tetrazoles Chemical class 0.000 title abstract 2
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 102100031366 Ankyrin-1 Human genes 0.000 abstract 1
- 101710191059 Ankyrin-1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente descripción proporciona algunos derivados de tetrazol que son inhibidores de potencial de receptor transitorio anquirina 1 (TRPA1) y que, por ende, son útiles para el tratamiento de las enfermedades que se pueden tratar mediante inhibición de TRPA1. Asimismo, se proporcionan composiciones farmacéuticas que lo contienen, y procesos para la preparación de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20182987 | 2020-06-29 | ||
| PCT/EP2021/067467 WO2022002780A1 (en) | 2020-06-29 | 2021-06-25 | Tetrazole derivatives as trpa1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016272A true MX2022016272A (es) | 2023-02-09 |
Family
ID=71401655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016272A MX2022016272A (es) | 2020-06-29 | 2021-06-25 | Derivados de tetrazol como inhibidores de trpa1. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11891403B2 (es) |
| EP (1) | EP4171571A1 (es) |
| JP (1) | JP2023533189A (es) |
| KR (1) | KR20230028546A (es) |
| CN (1) | CN116157130A (es) |
| AR (1) | AR122778A1 (es) |
| AU (1) | AU2021301140A1 (es) |
| BR (1) | BR112022021386A2 (es) |
| CA (1) | CA3182143A1 (es) |
| CL (1) | CL2022003325A1 (es) |
| CO (1) | CO2022016762A2 (es) |
| CR (1) | CR20220668A (es) |
| DO (1) | DOP2022000270A (es) |
| EC (1) | ECSP22088958A (es) |
| IL (1) | IL299172A (es) |
| MX (1) | MX2022016272A (es) |
| PE (1) | PE20240594A1 (es) |
| TW (1) | TW202216729A (es) |
| WO (1) | WO2022002780A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4323368A1 (en) | 2021-04-14 | 2024-02-21 | Boehringer Ingelheim International GmbH | 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| EP4323368A1 (en) | 2021-04-14 | 2024-02-21 | Boehringer Ingelheim International GmbH | 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors |
-
2021
- 2021-06-24 US US17/356,782 patent/US11891403B2/en active Active
- 2021-06-25 KR KR1020237003323A patent/KR20230028546A/ko unknown
- 2021-06-25 PE PE2022003064A patent/PE20240594A1/es unknown
- 2021-06-25 JP JP2022578725A patent/JP2023533189A/ja active Pending
- 2021-06-25 BR BR112022021386A patent/BR112022021386A2/pt unknown
- 2021-06-25 CN CN202180045923.7A patent/CN116157130A/zh active Pending
- 2021-06-25 EP EP21735302.8A patent/EP4171571A1/en active Pending
- 2021-06-25 MX MX2022016272A patent/MX2022016272A/es unknown
- 2021-06-25 CR CR20220668A patent/CR20220668A/es unknown
- 2021-06-25 AU AU2021301140A patent/AU2021301140A1/en active Pending
- 2021-06-25 CA CA3182143A patent/CA3182143A1/en active Pending
- 2021-06-25 IL IL299172A patent/IL299172A/en unknown
- 2021-06-25 WO PCT/EP2021/067467 patent/WO2022002780A1/en active Application Filing
- 2021-06-28 TW TW110123498A patent/TW202216729A/zh unknown
- 2021-06-28 AR ARP210101794A patent/AR122778A1/es unknown
-
2022
- 2022-11-21 EC ECSENADI202288958A patent/ECSP22088958A/es unknown
- 2022-11-22 CO CONC2022/0016762A patent/CO2022016762A2/es unknown
- 2022-11-25 CL CL2022003325A patent/CL2022003325A1/es unknown
- 2022-11-30 DO DO2022000270A patent/DOP2022000270A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022016762A2 (es) | 2022-12-09 |
| CN116157130A (zh) | 2023-05-23 |
| JP2023533189A (ja) | 2023-08-02 |
| US20210403482A1 (en) | 2021-12-30 |
| TW202216729A (zh) | 2022-05-01 |
| DOP2022000270A (es) | 2023-01-15 |
| ECSP22088958A (es) | 2022-12-30 |
| KR20230028546A (ko) | 2023-02-28 |
| WO2022002780A1 (en) | 2022-01-06 |
| CR20220668A (es) | 2023-03-10 |
| US11891403B2 (en) | 2024-02-06 |
| CL2022003325A1 (es) | 2023-03-31 |
| IL299172A (en) | 2023-02-01 |
| AU2021301140A1 (en) | 2022-11-10 |
| CA3182143A1 (en) | 2022-01-06 |
| EP4171571A1 (en) | 2023-05-03 |
| BR112022021386A2 (pt) | 2023-01-10 |
| AR122778A1 (es) | 2022-10-05 |
| PE20240594A1 (es) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550604A1 (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| MX2021012549A (es) | Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa). | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MX2019007234A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos. | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2022013223A (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2. | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2022016357A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| MX2022016272A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX2023004009A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| MX2023011828A (es) | Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1. | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
| ZA202100955B (en) | Thrombin inhibitors, formulations, and uses thereof | |
| MX2023011830A (es) | Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1. | |
| EA202192859A1 (ru) | ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ | |
| MX2021008748A (es) | Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. |